

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Docket No.: PF112P3C2US
Hu et al.

Application No.: Not Yet Assigned Group Art Unit: N/A

Filed: Concurrently Herewith Examiner: Not Yet Assigned

For: Vascular Endothelial Growth Factor 2

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-GT listed on the attached Form PTO/SB/08.

References FZ-GT and the accompanying exhibits were brought to the attention of the Applicants in connection with an opposition to an Australian application that essentially corresponds to the U.S. priority application in this case.

Copies of references AA-AU and AY-FY were submitted by Applicants or cited by the Examiner in connection with U. S. Application No. 09/623,725, filed November 20, 2000, and references AV-AX and FZ-GT were submitted by Applicants or cited by the Examiner in connection with U.S. Application No. 10/084,488, filed February 28, 2002, to each of which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the above-listed files for copies of references AA-GT referenced herein.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning

the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed reference(s) is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner acknowledge receipt of the above-referenced documents in the file of the instant application.

Pursuant to 37 C.F.R. § 1.97(b), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to our Deposit Account No. 08-3425.

Dated: October 30, 2003

Respectfully submitted,



Melissa J. Pytel
Registration No.: 41,512
HUMAN GENOME SCIENCES, INC.
9410 Key West Avenue
Rockville, Maryland 20850
(301) 610-5764

MMW/MJP/ba

Please type a plus sign (+) inside this box →

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Unassigned
				Filing Date	Herewith
				First Named Inventor	HU et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	11	Attorney Docket Number	PF112P3C2US

U.S. PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
AA	6,040,157			Hu et al.	03-21-2000	
AB	5,935,820			Hu et al.	08-10-1999	
AC	5,932,540			Hu et al.	08-03-1999	
AD	5,633,147			Meissner et al.	05-27-1999	
AE	5,283,354			Lemischka	02-01-1994	
AF	5,240,848			Keck et al.	08-31-1993	
AG	5,234,908			Szabo et al.	08-10-1993	
AH	5,194,596			Tischer et al.	03-16-1993	
AI	5,861,301			Terman et al.	01-19-1999	
AJ	5,840,693			Eriksson et al.	11-24-1999	
AK	5,073,492			Chen et al.	12-17-1991	
AL	5,219,739			Tischer et al.	06-15-1993	
AM	5,326,695			Andersson et al.	07-05-1994	
AN	5,607,918			Eriksson et al.	03-04-1997	
AO	5,776,755			Alitalo et al.	07-07-1998	
AP	08/510133				08/1995	
AQ	08/585895				01/1996	
AR	08/601132				02/1996	
AS	08/671573				06/1996	
AT	60/003491				09/1995	
AU	08/554374				11/1995	
AV	6,221,839			Alitalo et al.	04/2001	
AW	6,245,530			Alitalo et al.	06/2001	
AX	6,403,088			Alitalo et al.	06/2002	

Examiner Signature	Date Considered
--------------------	-----------------

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Unassigned
Sheet	2	of	11	Filing Date	Herewith
				First Named Inventor	HU et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	PF112P3C2US

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear ¹
		Office ³	Number ⁴			
	AY	WO	99/46364	Human Genome Sciences, Inc.	09-16-1999	
	AZ	WO	98/33917	Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd.	06-08-1998	
	BA	WO	98/07832	Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd. Oy	02-26-1998	
	BB	WO	96/39515	Human Genome Sciences, Inc.	12-12-1996	
	BC	WO	96/05856	Human Genome Sciences, Inc.	02-29-1996	
	BD	WO	00/75163	Human Genome Sciences	12-14-2000	
	BE	WO	96/39515	Human Genome Sciences	12-12-1996	
	BF	WO	95/24473	Human Genome Sciences	12-14-1995	
	BG	EP	0 476983	Merck & Co., Inc.	03-25-1992	
	BH	WO	95/24414	Human Genome Sciences, Inc.	09-14-1995	
	BI	WO	95/19985	Human Genome Sciences, Inc.	07-27-1995	
	BJ	WO	92/14748	American Cyanamid Co.	09-03-1992	
	BK		9-403464	Human Genome Sciences, Inc.	01-31-1996	
	BL	WO	99/21590	Merck & Co.	05-06-1999	
	BM	WO	99/08522	Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd.	02-25-1999	
	BN	WO	98/56936	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	12-17-1998	
	BO	WO	98/49300	Collateral Therapeutics	11-05-1998	
	BP	WO	98/39035	The Wistar Institute of Anatomy & Biology	09-11-1998	
	BQ	WO	98/24811	ZymoGenetics, Inc.	06-11-1998	

Examiner Signature		Date Considered
--------------------	--	-----------------

¹Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Unassigned
Sheet	3	of	11	Filing Date	Herewith
				First Named Inventor	HU et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	PF112P3C2US

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴			
	BR	WO	98/06844	Human Genome Sciences, Inc.	02-19-1998	
	BS		710696	Genentech, Inc.	09-30-1999	
	BT		0-476983	Bayne et al.	03-25-1992	
	BU		0-506477	Bayne et al.	09-30-1992	
	BV	WO	97/05250	University of Helsinki	02-13-1997	
	BW	WO	97/09427	Genentech, Inc.	03-13-1997	
	BX	WO	97/17442	Immunex Corporation	05-15-1997	

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	BY	ACHEN et al., "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor-2 (Flk1) and VEGF receptor 3 (Flt4)," Proc. Natl. Acad. Sci. (USA), 95(2): 548-553 (1998).
	BZ	ALDERSON, et al. (1999) Vascular endothelial cell growth factor (VEGF)-2 enhances the development of rat photoreceptor cells in vitro. Keystone Symposia, Ocular Cell and Molecular Biology, 202. (Abstract provided)
	CA	ANDERSSON et al., "Assignment of interchain disulfide bonds in platelet-derived growth factor (PDGF) and evidence for agonist activity of monomeric PDGF," J. Biol. Chem., 267(16): 11260-11266 (1992).
	CB	ANDERSSON W.F., "Human gene therapy," Science, 256:808-813 (1992).
	CC	Aprelikova et al., "FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-pter," Cancer Research, 52:746-748 (1992).
	CD	DIGNAM et al., "Balbiani ring 3 in <i>chironomus tentans</i> encodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar," Gene 88:133-140 (1990).
	CE	FERRARA et al., "Molecular and biological properties of the vascular endothelial growth factor family of proteins," Endocrine Rev. 13(1): 18-32 (1992).
	CF	FINNERTY et al., "Molecular cloning of murine FLT and FLT4," Oncogene 8(11): 2293-2298 (1993).
	CG	HELDIN et al., "Structure of platelet-derived growth factor: implications for functional properties," Growth Factors 8:245-252 (1993).
	CH	EICHMANN et al., "Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors," Development 125(4): 743-752 (1998).

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Unassigned
Sheet	4	of	11	Filing Date	Herewith
				First Named Inventor	HU et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	PF112P3C2US

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	CI	PAJUSOLA <i>et al.</i> , "FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines," <i>Cancer Research</i> 52:5738-5743 (1992).
	CJ	LEUNG <i>et al.</i> , "Vascular endothelial growth factor is a secreted angiogenic mitogen," <i>Science</i> 246:1306-1309 (1989).
	CK	BREIER <i>et al.</i> , "Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation," <i>Development</i> 114:521-532 (1992).
	CL	BELL <i>et al.</i> , "Human epidermal growth factor precursor: cDNA sequence, expression <i>in vitro</i> and gene organization," <i>Nucl. Acids Res.</i> 14(21): 8427-8446 (1986).
	CM	BERSE <i>et al.</i> , Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors," <i>Mol. Biol. Cell.</i> 3:211-220 (1992).
	CN	BETSHOLTZ <i>et al.</i> , "cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumor cell lines," <i>Nature</i> 320:695-699 (1986).
	CO	CLAFFEY <i>et al.</i> , "Vascular endothelial growth factor," <i>J. Biol. Chem.</i> 267(23): 16317-16322 (1992).
	CP	CORSON <i>et al.</i> , "Fibrillin binds calcium and is coded by cDNAs that reveal a multidomain structure and alternatively spliced exons at the 5' end," <i>Genomics</i> 17:476-484 (1993).
	CQ	FERRARA <i>et al.</i> , "The vascular endothelial growth factor family of polypeptides," <i>J. Cellular Biochemistry</i> 47:211-218 (1991).
	CR	GEORGE <i>et al.</i> , "Current Methods in Sequence Comparison and Analysis," Macromolecular Seq. and Syn. Selected Meth – Application (Alan R. Liss), pp. 127-149 (1988).
	CS	HU <i>et al.</i> , "A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial smooth muscle cells," <i>FASEB J.</i> , 11:498-504 (1997).
	CT	JOUKOV <i>et al.</i> , "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases," <i>EMBO J.</i> 15(2): 290-298 (1996).
	CU	JOUKOV <i>et al.</i> , "Proteolytic processing regulates receptor specificity and activity of VEGF-C," <i>EMBO J.</i> 16(13): 3898-3911 (1997).
	CV	KAIPAINEN <i>et al.</i> , "The related FLT4, FLT1 and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells," <i>J. Exp. Med.</i> 178:2077-2088 (1993).

Examiner Signature		Date Considered
--------------------	--	-----------------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Unassigned
Sheet	5	of	11	Filing Date	Herewith
				First Named Inventor	HU et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	PF112P3C2US

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	CW	KECK <i>et al.</i> , "Vascular permeability factor, an endothelial cell mitogen related to PDGF," <i>Science</i> 246: 1309 (1989).
	CX	KINGSLEY, D., "The TGF- β superfamily: new members, new receptors, and new genetic tests of function in different organisms," <i>Genes & Development</i> 8: 133-146 (1994).
	CY	KUKK <i>et al.</i> , "VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development," <i>Development</i> 122: 3829-37 (1996).
	CZ	LEE <i>et al.</i> , "Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4," <i>Proc. Natl. Acad. Sci. (USA)</i> , 93:1988-1992 (1996).
	DA	MAGLIONE <i>et al.</i> , "Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14," <i>Oncogene</i> 8:925-931 (1993).
	DB	MAGLIONE <i>et al.</i> , "Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor," <i>Proc. Natl. Acad. Sci. (USA)</i> , 88:9267-9271 (1991).
	DC	MASSAGUE, J., "The transforming growth factor-beta family," <i>Annu. Rev. Cell Biol.</i> 6:597-641 (1990).
	DD	MATTHEWS <i>et al.</i> , "A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit," <i>Proc. Natl. Acad. Sci. (USA)</i> , 88:9026-9030 (1991).
	DE	MILLAUER <i>et al.</i> , "High affinity VEGF binding and developmental expression suggest FLK-1 as a major regulator of vasculogenesis and angiogenesis," <i>Cell</i> 72:835-846 (1993).
	DF	MILLAUER <i>et al.</i> , "Glioblastoma growth inhibited <i>in vivo</i> by a dominant-negative Flk-1 mutant," <i>Nature</i> 367:576-579 (1994).
	DG	OLTVAI <i>et al.</i> , "Bcl-2 heterodimerizes <i>in vivo</i> with a conserved homolog, bax, that accelerates programmed cell death," <i>Cell</i> 74:609-619 (1993).
	DH	PAULSSON <i>et al.</i> , "The balbani ring 3 gene in <i>chironomus tentans</i> has a diverged repetitive structure split by many introns," <i>J. Mol. Biol.</i> 211:331-349 (1990).
	DI	PAJUSOLA <i>et al.</i> , "Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts," <i>Oncogene</i> 8:2931-2937 (1993).
	DJ	TISCHER <i>et al.</i> , "Vascular endothelial growth factor: A new member of the platelet-derived growth factor gene family," <i>Biochem. & Biophys. Res. Comms.</i> 165(3): 1198-1206 (1989).
	DK	TANAKA <i>et al.</i> , "DNA sequence encoding the amino-terminal region of the human c-src protein: implications of sequence divergence among src-type kinase oncogenes," <i>Mol. Cell Biol.</i> 7(5): 1978-1983 (1987).

Examiner Signature	Date Considered
--------------------	-----------------

¹Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Unassigned
Sheet	6	of	11	Filing Date	Herewith
				First Named Inventor	HU et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	
				PF112P3C2US	

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		T ²	
DL	TERMAN <i>et al.</i> , "Identification of a new endothelial cell growth factor receptor tyrosine kinase," <i>Oncogene</i> 6:1677-1683 (1991).		
DM	TERMAN <i>et al.</i> , "Identification of the kdr tyrosine kinase as a receptor for vascular endothelial cell growth factor," <i>Biochem. Biophys. Res. Commun.</i> 187(3): 1579-1586 (1992).		
DN	TSUJIMOTO <i>et al.</i> , "Analysis of the structure, transcripts, and protein products of <i>bcl-2</i> , the gene involved in human follicular lymphoma," <i>Proc. Natl. Acad. Sci (USA)</i> , 83:5214-5218 (1986).		
DO	TISCHER <i>et al.</i> , "The Human Gene for Vascular Endothelial Growth Factor," <i>J. Biol. Chem.</i> 266(18): 11947-11954 (1991).		
DP	FRIEDMAN, T., "A brief history of gene therapy," <i>Nat. Genetics</i> 2:93-98 (1992).		
DQ	WILLIAMS, R.S. "Southwestern internal medicine conference: prospects for gene therapy of ischemic heart disease," <i>Am. J. Med. Sci.</i> 306(2): 129-136 (1993).		
DR	HOCKEL <i>et al.</i> , "Therapeutic angiogenesis," <i>Arch. Surg.</i> 128:423-429 (1993).		
DS	GUZMAN <i>et al.</i> "Efficient gene transfer into myocardium by direct injection of adenovirus vectors," <i>Circ. Res.</i> 73:1202-1207 (1993).		
DT	BELLOMO <i>et al.</i> , "Mice Lacking the Vascular Endothelial Growth Factor-B Gene (Vegfb) Have Smaller Hearts, Dysfunctional Coronary Vasculature, and Impaired Recovery From Cardiac Ischemia," <i>Circ. Research</i> 89(2): e29-e35 (2000).		
DU	COCKERILL <i>et al.</i> , "Angiogenesis: Models and Modulators" <i>Intl. Rev. Cytology</i> 159:113-160 (1995).		
DV	GAMBLE <i>et al.</i> , "Regulation of In Vitro Capillary Tube Formation by Anti-Integrin Antibodies," <i>J. Cell. Bio.</i> 121(4): 931-943 (1993).		
DW	GOLDSPIEL <i>et al.</i> , "Human Gene Therapy," <i>Clinical Pharmacy</i> 12: 488-505 (1993).		
DX	GRIMMOND <i>et al.</i> , "Cloning and Characterization of a Novel Human Gene Related to Vascular Endothelial Growth Factor," <i>Genome Research</i> 6:124-131 (1996).		
DY	HYDE <i>et al.</i> , "Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy," <i>Nature</i> 362: 250-255 (1993).		
DZ	KAY <i>et al.</i> , "In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs," <i>Science</i> 262:117-119 (1993).		
EA	KOLODKA <i>et al.</i> , "Hepatic Gene Therapy: Efficient Retroviral-Mediated Gene Transfer into Rat Hepatocytes in Vivo," <i>Somatic Cell and Molecular Genetics</i> 19(5):491-497 (1993).		
EB	LITWIN <i>et al.</i> , "Role of Cytokines in Endothelial Cell Functions," <i>Human Cytokines</i> 7:101-129 (1995).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Unassigned
Sheet	7	of	11	Filing Date	Herewith
				First Named Inventor	HU et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	PF112P3C2US

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	EC	SHIBUYA <i>et al.</i> , "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (<i>flt</i>) closely related to the <i>fms</i> family," <i>Oncogene</i> 5:19-524 (1990).			T ²
	ED	SILINS <i>et al.</i> , "Analysis of the Promoter Region of the Human VEGF-Related Factor Gene," <i>Biochem. Biophys. Res. Comm.</i> 230: 413-418 (1997).			
	EE	STEWART <i>et al.</i> , "Insulin delivery by somatic cell gene therapy," <i>J of Mol. Endocrinology</i> 11: 335-341 (1993).			
	EF	TOWNSON <i>et al.</i> , "Characterization of the Murine VEGF-Related Factor Gene," <i>Biochem. & Biophys. Res. Comms.</i> 220: 922-928 (1996).			
	EG	WALSH <i>et al.</i> , "Gene Therapy for Human Hemoglobinopathies," <i>P.S.E.B.M.</i> 204(3):289-300 (Dec. 1993).			
	EH	YOUNEY, et al. (2000) Vascular Endothelial Cell Growth Factors Promote the In Vitro Development of Rat Photoreceptor Cells. <i>J. Neuroscience</i> , 20: 6781 - 6788.			
	EI	YOUNEY, et al. (1999) Vascular Endothelial Cell Growth Factor (VEGF)-2 Enhances the Development of Rat Photoreceptor Cells In Vitro. <i>Soc. Cell Biology</i> , 227. (Abstract provided)			
	EJ	GenBank Accession No. X68203, APRELIKOVÁ <i>et al.</i> , "H.sapiens mRNA for FLT4, class III receptor tyrosine kinase," November 30, 1993.			
	EK	GenBank Accession No. M95200, CLAFFEY <i>et al.</i> , "Mouse vascular endothelial growth factor mRNA, complete cds," April 27, 1993.			
	EL	GenBank Accession No. M24160, DIGNAM <i>et al.</i> , "C.tentans 185-kd secretory protein (sp185) mRNA, partial cds, clone pCt185," April 26, 1993.			
	EM	GenBank Accession No. M24276, DIGNAM <i>et al.</i> , "C.tentans 140-kd secretory protein (sp140) mRNA, partial cds, clone pCt140.1," April 26, 1993.			
	EN	GenBank Accession No. M24277, DIGNAM <i>et al.</i> , "C.tentans 140-kd secretory protein (sp140) mRNA, partial cds, clone pCt140.2," April 26, 1993.			
	EO	GenBank Accession No. D88689, FINNERTY <i>et al.</i> , "Mus musculus mRNA for flt-1, complete cds," April 14, 2000.			
	EP	GenBank Accession No. L07296, FINNERTY <i>et al.</i> , "Mus musculus receptor tyrosine kinase (FLT4) mRNA, complete cds," August 9, 1993.			
	EQ	GenBank Accession No. X54936, MAGLIONE <i>et al.</i> , "H.sapiens mRNA for placenta growth factor (PIGF)," November 12, 1991.			
	ER	GenBank Accession No. S57152, MAGLIONE <i>et al.</i> , "Homo sapiens placenta growth factor 2 (PIGF-2) gene, partial cds," March 5, 2001.			
	ES	GenBank Accession No. X59397, MATTHEWS <i>et al.</i> , "Mouse Flk-1 mRNA for a tyrosine kinase receptor," November 6, 1991.			

Examiner Signature	Date Considered
--------------------	-----------------

¹Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Unassigned
Sheet	8	of	11	Filing Date	Herewith
				First Named Inventor	HU et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	PF112P3C2US

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	ET	GenBank Accession No. X52263, PAULSSON <i>et al.</i> , "C.tentans balbiani ring 3 (BR3) gene," December 18, 1992.			
	EU	GenBank Accession No. M63971, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 1," August , 1993.			
	EV	GenBank Accession No. M63972, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 2," August 3, 1993.			
	EW	GenBank Accession No. M63973, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 3," August 3, 1993.			
	EX	GenBank Accession No. M63974, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 4," August 3, 1993.			
	EY	GenBank Accession No. M63975, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 5," August 3, 1993.			
	EZ	GenBank Accession No. M63976, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 6," August 3, 1993.			
	FA	GenBank Accession No. M63977, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 7," August 3, 1993.			
	FB	GenBank Accession No. M63978, TISCHER <i>et al.</i> , "Human vascular endothelial growth factor gene, exon 8," August 3, 1993.			
	FC	GenBank Accession No. M27281, KECK <i>et al.</i> , "Human vascular permeability factor mRNA, complete cds," August 3, 1993.			
	FD	GenBank Accession No. X04571, BELL <i>et al.</i> , "Human mRNA for kidney epidermal growth factor (EGF) precursor," March 21, 1995.			
	FE	GenBank Accession No. X63556, CORSON <i>et al.</i> , "H. sapiens mRNA for fibrillin," February 17, 1997.			
	FF	GenBank Accession No. L19896, CORSON <i>et al.</i> , "Human fibrillin (FBN1) gene, 5'end including alternative exons A, B, and C, and exon M," November 8, 1994.			
	FG	GenBank Accession No. L04947, TERMAN <i>et al.</i> , "Homo sapiens (clones BT3.081.8, BT3.129.5 and BT4.169," January 6, 1995.			
	FH	GenBank Accession No. M16237, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 2," January 13, 1995.			
	FI	GenBank Accession No. M16243, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 3," January 13, 1995.			
	EJ	GenBank Accession No. M16244, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 4, January 13, 1995.			
	FK	GenBank Accession No. M16245, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 5," January 13, 1995.			
Examiner Signature				Date Considered	

¹Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Unassigned
Sheet	9	of	11	Filing Date	Herewith
				First Named Inventor	HU et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	PF112P3C2US

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
FL	GenBank Accession No. K03212, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 6," January 13, 1995.	T ²
FM	GenBank Accession No. K03213, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 7," January 13, 1995.	T ²
FN	GenBank Accession No. K03214, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 8", January 13, 1995.	T ²
FO	GenBank Accession No. K03215, ANDERSON <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 9," January 13, 1995.	T ²
FP	GenBank Accession No. K03216, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 10, January 13, 1995.	T ²
FQ	GenBank Accession No. K03217, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 11," January 13, 1995.	T ²
FR	GenBank Accession No. K03218, TANAKA <i>et al.</i> , "Human c-src-1 proto-oncogene, exon 12," January 13, 1995.	T ²
FS	GenBank Accession No. M13994, TSUJIMOTO <i>et al.</i> , "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-2-alpha protein, complete cds," October 31, 1994.	T ²
FT	GenBank Accession No. M13995, TSUJIMOTO <i>et al.</i> , "Human B-cell leukemia/lymphoma 2 (bcl-2) proto-oncogene mRNA encoding bcl-3-beta protein, complete cds," October 31, 1994.	T ²
FU	GenBank Accession No. L22473, OLTVAI <i>et al.</i> , "Human Bax alpha mRNA, complete cds, "December 15, 1993.	T ²
FV	GenBank Accession No. L22474, OLTVAI <i>et al.</i> , "Human Bax beta mRNA, complete cds," December 13, 1993.	T ²
FW	GenBank Accession No. AJ000185, ACHEN <i>et al.</i> , "Homo Sapiens mRNA for vascular endothelial growth factor-D," February 11, 1998.	T ²
FX	International Search Report, Application No. PCT/US99/05021.	T ²
FY	International Search Report, Application No. PCT/US94/05291.	T ²

Examiner Signature		Date Considered
--------------------	--	-----------------

¹ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	Unassigned
Sheet	10	of	11	Filing Date	Herewith
				First Named Inventor	HU et al.
				Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	PF112P3C2US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	²
	FZ	Statutory Declaration of John Stanley Mattick, executed on December 12, 2000, and Exhibits JSM1-JSM4	
	GA	Statutory Declaration of Nicholas Kim Hayward, executed on December 8, 2000, and Exhibits NKH1-2	
	GB	Statutory Declaration of Jennifer Ruth Gamble, executed on December 12, 2000, and Exhibits JRG1-3	
	GC	Statutory Declaration of Tom Rapoport, executed on December 13, 2000, and Exhibits TP1-2	
	GD	Statutory Declaration of Stuart A. Aaronson, executed on December 14, 2000, and Curriculum Vitae of Stuart A. Aaronson	
	GE	Statutory Declaration of Susan Power, executed on December 13, 2000, Appendices 1-2 and Figure 1	
	GF	Statutory Declaration of Gary Baxter Cox, executed on December 13, 2000, and Exhibits GBC-1 – GBC 23	
	GG	Statutory Declaration of Peter Adrian Walton Rogers, executed on November 12, 2001, and exhibits PAWR-1 through PAWR-14	
	GH	Statutory Declaration of Peter Adrian Walton Rogers, executed on February 16, 2000, and exhibit 1	
	GI	Statutory Declaration of Kari Alitalo executed on February 15, 2000, and exhibits 1-3	
	GJ	Statutory Declaration of Francis John Ballard, executed on February 16, 2000, and exhibit 1	
	GK	Statutory Declaration of Kari Alitalo, executed on September 24, 2001, and exhibits 1-2	
	GL	Statutory Declaration of Francis John Ballard, executed on December 12, 2001 and exhibit 1	
	GM	Statutory Declaration of Susan Power, executed on March 22, 2002, and accompanying Appendices I to IV	
	GN	Statutory Declaration of Nicholas Kim Hayward, executed on March 26, 2002	
	GO	Statutory Declaration of Stuart A. Aaronson, executed on March 22, 2002, and accompanying Appendices I to III	

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				<p><i>Complete if Known</i></p>	
				Application Number	Unassigned
				Filing Date	Herewith
				First Named Inventor	HU et al.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	11	of	11	Attorney Docket Number	PF112P3C2US

Examiner Signature	Date Considered	
-----------------------	--------------------	--